Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Liabilities: 2011-2024

Historic Total Liabilities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $122.2 million.

  • Agios Pharmaceuticals' Total Liabilities fell 38.61% to $101.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.4 million, marking a year-over-year decrease of 38.61%. This contributed to the annual value of $122.2 million for FY2024, which is 3.06% down from last year.
  • As of FY2024, Agios Pharmaceuticals' Total Liabilities stood at $122.2 million, which was down 3.06% from $126.1 million recorded in FY2023.
  • Over the past 5 years, Agios Pharmaceuticals' Total Liabilities peaked at $453.5 million during FY2020, and registered a low of $122.2 million during FY2024.
  • Its 3-year average for Total Liabilities is $128.7 million, with a median of $126.1 million in 2023.
  • In the last 5 years, Agios Pharmaceuticals' Total Liabilities surged by 81.23% in 2020 and then slumped by 67.86% in 2021.
  • Agios Pharmaceuticals' Total Liabilities (Yearly) stood at $453.5 million in 2020, then tumbled by 67.86% to $145.8 million in 2021, then dropped by 5.39% to $137.9 million in 2022, then fell by 8.56% to $126.1 million in 2023, then dropped by 3.06% to $122.2 million in 2024.